BioSpace News Archive

A Canadian Medical Device Licence was issued September 24 by Health Canada for Reveal 35C™, created by KA Imaging - a University of Waterloo spin-off company. Reveal is a portable dual-energy X-ray detector that enables bone and soft-tissue differentiation without motion

“These preclinical studies transform our understanding of how drug coated balloons deliver drug to the artery and why there is no class effect, while also providing tools for understanding the role of tissue stiffening with disease. The combination of mechanistic insight with predictive modeling can help accelerate development of new technologies such as those including sirolimus analogs,” said Sahil A. Parikh, M.D., Director of Endovascular Services at th

StopAfib.org’s annual “Get in Rhythm. Stay in Rhythm. ® Atrial Fibrillation Patient Conference” is for those living with atrial fibrillation (the most common irregular heartbeat, which increases stroke risk by 500%). For the first time ever, the conference is virtual, which means anyone anywhere in the world has the good fortune

Ongoing Phase I/II trial to enroll up to 6 additional patients in Cohort 2 while planning for next steps in program; further trial updates expected by the end of 2020

First-Ever Study to Have Evaluated the Safety and Efficacy of an Investigational RNAi Therapeutic in Infants and Children Under the Age of Six

Medeor Therapeutics, Inc. announced that interim results from the company’s MERCURY Phase 3 clinical trial will be presented by lead Principal Investigator Dr. Dixon Kaufman of the University of Wisconsin at the American Society of Nephrology Kidney Week 2020, being held virtually from October 19-25, 2020.

Bruker Corporation announces the recent acquisition of the Integrated Proteomics Pipeline search engine and proteomics workflow software platform.

Winn-Dixie is partnering with American Cancer Society’s Making Strides Against Breast Cancer during the month of October to raise funds and spread hope to those impacted by breast cancer. Now through Nov. 3, customers in Alabama, Mississippi and Columbus, Georgia can help their neighbors fighting breast cancer by rounding

Carmot Therapeutics, Inc., a biotechnology company focused on bringing transformative therapies to patients with metabolic diseases, announced a $47 million series C financing.

Sonoma Biotherapeutics, a privately held company developing regulatory T-cell therapies for autoimmune and degenerative diseases, announced that it has raised an additional $30 million from investors in its Series A financing, bringing the total to $70 million.